The report examined the cost-effectiveness of Pfizer’s Paxlovid, Merck’s molnupiravir, GlaxoSmithKline and Vir’s sotrovimab and generic drug fluvoxamine, which has yet to receive approval from the FDA to treat COVID-19 but can be used off-label to treat the condition.
Sotrovimab had the highest cost per hospitalization averted at $91,000, and its cost per quality-adjusted life year was $69,000.
Molnupiravir’s cost per hospitalization averted was $63,000, and its cost per quality-adjusted life year was $55,000.
Paxlovid’s cost per hospitalization averted was $21,000, and its cost per quality-adjusted life year was $18,000.
Fluvoxamine cost per hospitalization averted was $7,000, and its cost per quality-adjusted life year was $6,000.
ICER considers anything below $100,000 per quality-adjusted life year to be cost-effective.
Read the full report here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
